CDKN2A and astrocytoma (excluding glioblastoma): In the present study, we investigated the prognostic role of CDKN2A homozygous deletion in WHO grade 4 CNS gliomas, including IDH-mutant astrocytoma’s and IDH-wildtype glioblastomas.